Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 17, 2024 - Issue
Submit an article Journal homepage
63
Views
0
CrossRef citations to date
0
Altmetric
SHORT REPORT

Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study

Matteo MegnaSection of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyView further author information
,
Angelo RuggieroSection of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyORCID Iconhttps://orcid.org/0000-0002-4658-7391View further author information
ORCID Icon,
Nello TommasinoSection of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyORCID Iconhttps://orcid.org/0009-0002-7997-1784View further author information
ORCID Icon,
Claudio BresciaSection of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyView further author information
,
Fabrizio MartoraSection of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyORCID Iconhttps://orcid.org/0000-0003-2523-050XView further author information
ORCID Icon,
Sara CacciapuotiSection of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyView further author information
&
Luca PotestioSection of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5940-0592View further author information
ORCID Icon show all
Pages 1037-1042 | Received 16 Feb 2024, Accepted 29 Apr 2024, Published online: 07 May 2024

References

  • Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi:10.1016/S0140-6736(14)61909-7
  • Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18–ii25. doi:10.1136/ard.2004.033217
  • Yamazaki F. Psoriasis: comorbidities. J Dermatol. 2021;48(6):732–740. doi:10.1111/1346-8138.15840
  • Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006
  • Bakshi H, Nagpal M, Singh M, Dhingra GA, Aggarwal G. Treatment of psoriasis: a comprehensive review of entire therapies. Curr Drug Saf. 2020;15(2):82–104. doi:10.2174/1574886315666200128095958
  • Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi:10.3390/ijms20061475
  • Ruggiero A, Camela E, Potestio L, Fabbrocini G, Megna M. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(12):1445–1451. doi:10.1080/14740338.2022.2160447
  • Caldarola G, Galluzzo M, Bernardini N, et al. Tildrakizumab in moderate-to-severe plaque psoriasis: a multicenter, retrospective, real-life study. Dermatol Ther. 2022;35(6):e15488. doi:10.1111/dth.15488
  • Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M. Tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52 weeks real-life retrospective study. Clin Cosmet Invest Dermatol. 2023;16:529–536. doi:10.2147/CCID.S402183
  • Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2023;37(1):93–103. doi:10.1111/jdv.18594
  • Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941. doi:10.1111/dth.15941
  • Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J DermatolTreat. 2022;33(6):2813–2820. doi:10.1080/09546634.2022.2081655
  • Giordano S, Dapavo P, Ortoncelli M, et al. Interclass switch between IL17 and IL23 inhibitors in psoriasis: a real-life, long-term, single-center experience. J Clin Med. 2023;12(24):7503. doi:10.3390/jcm12247503
  • Megna M, Potestio L, Fabbrocini G, Cinelli E. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34(5):e15030. doi:10.1111/dth.15030
  • Di Brizzi EV, Buononato D, Benvenuto P, et al. Effectiveness and safety after a switch to tildrakizumab: a real world multicenter Italian study in psoriasis. Dermatol Pract Concept. 2023;13(4):e2023215. doi:10.5826/dpc.1304a215
  • Tsai YC, Tsai TF. Switching biologics in psoriasis - practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13(5):493–503. doi:10.1080/17512433.2020.1767590
  • Megna M, Potestio L, Battista T, et al. Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics. Clin Exp Dermatol. 2022;47(12):2310–2312. doi:10.1111/ced.15395
  • Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;32(6):537–552. doi:10.1080/13543784.2023.2219387
  • Vu A, Ulschmid C, Gordon KB. Anti-IL 23 biologics for the treatment of plaque psoriasis [published correction appears in Expert Opin Biol Ther. 2022 Dec 5:1–4]. Expert Opin Biol Ther. 2022;22(12):1489–1502. doi:10.1080/14712598.2022.2132143
  • Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L. Long-term efficacy and safety of risankizumab for moderate to severe psoriasis: a 2-year real-life retrospective study. J Clin Med. 2023;12(9):3233. doi:10.3390/jcm12093233
  • Ly K, Smith MP, Thibodeaux Q, Reddy V, Liao W, Bhutani T. Anti IL-17 in psoriasis. Expert Rev Clin Immunol. 2019;15(11):1185–1194. doi:10.1080/1744666X.2020.1679625
  • Megna M, Potestio L, Camela E, Fabbrocini G, Ruggiero A. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;35(9):e15667. doi:10.1111/dth.15667

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.